Unveiling New Chapters in Medullary Thyroid Carcinoma Therapy: Advances in Molecular Genetics and Targeted Treatment Strategies

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Oct 23

PMID 39439561

Authors

Jia-Xuan Huai

Fang Wang

Wen-Hui Zhang

Yan Lou

Gao-Xiang Wang

Li-Ji Huang

Jing Sun

Xi-Qiao Zhou

Affiliations

Soon will be listed here.

Abstract

Medullary Thyroid Carcinoma (MTC), a neuroendocrine malignancy that arises from the calcitonin-secreting parafollicular C-cells of the thyroid, constitutes a minor yet impactful fraction of thyroid malignancies. Distinguished by its propensity for aggressive growth and a pronounced tendency for metastasis, MTC poses formidable obstacles to the early diagnosis and therapeutic intervention. The molecular genetics of MTC, particularly the role of the RET gene and the RAS gene family, have been extensively studied, offering insights into the pathogenesis of the disease and revealing potential therapeutic targets. This comprehensive review synthesizes the latest advancements in the molecular genetics of MTC, the evolution of precision therapies, and the identification of novel biomarkers. We also discuss the implications of these findings for clinical practice and the future direction of MTC research.

References

Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V . Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience. 2019; 20:324-336. PMC: 6817656. DOI: 10.1016/j.isci.2019.09.030. View

Besharat Z, Abballe L, Cicconardi F, Bhutkar A, Grassi L, Le Pera L . Foxm1 controls a pro-stemness microRNA network in neural stem cells. Sci Rep. 2018; 8(1):3523. PMC: 5824884. DOI: 10.1038/s41598-018-21876-y. View

Mulligan L . RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014; 14(3):173-86. DOI: 10.1038/nrc3680. View

Heilmann A, Subbiah V, Wang K, Sun J, Elvin J, Chmielecki J . Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46. PMC: 4909575. DOI: 10.1159/000445978. View

Barletta J, Nose V, Sadow P . Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Endocr Pathol. 2021; 32(1):35-43. PMC: 9353617. DOI: 10.1007/s12022-021-09664-3. View

Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F . Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32(8):768-73. PMC: 4876348. DOI: 10.1200/JCO.2013.50.4357. View

Hadoux J, Elisei R, Brose M, Hoff A, Robinson B, Gao M . Phase 3 Trial of Selpercatinib in Advanced -Mutant Medullary Thyroid Cancer. N Engl J Med. 2023; 389(20):1851-1861. DOI: 10.1056/NEJMoa2309719. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Ban K, Feng S, Shao L, Ittmann M . RET Signaling in Prostate Cancer. Clin Cancer Res. 2017; 23(16):4885-4896. PMC: 5609835. DOI: 10.1158/1078-0432.CCR-17-0528. View

10.

Hincza-Nowak K, Kowalik A, Walczyk A, Palyga I, Gasior-Perczak D, Plusa A . Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021; 12(10). PMC: 8536131. DOI: 10.3390/genes12101534. View

11.

Chang Y, Chang C, Huang H, Lin C, Yeh K, Chang J . Detection of Molecular Alterations in Taiwanese Patients with Medullary Thyroid Cancer Using Whole-Exome Sequencing. Endocr Pathol. 2018; 29(4):324-331. DOI: 10.1007/s12022-018-9543-6. View

12.

Moura M, Cavaco B, Pinto A, Domingues R, Santos J, Cid M . Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009; 100(11):1777-83. PMC: 2695700. DOI: 10.1038/sj.bjc.6605056. View

13.

Shi X, Li C, Tan L, Wen S, Liao T, Zhang Y . Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. J Clin Endocrinol Metab. 2020; 106(1):120-132. DOI: 10.1210/clinem/dgaa701. View

14.

Wang N, Kjellin H, Sofiadis A, Fotouhi O, Juhlin C, Backdahl M . Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget. 2016; 7(16):21332-46. PMC: 5008288. DOI: 10.18632/oncotarget.7237. View

15.

Zheng X, Ji Q, Sun Y, Ge M, Zhang B, Cheng Y . Efficacy and safety of selpercatinib in Chinese patients with advanced -altered thyroid cancers: results from the phase II LIBRETTO-321 study. Ther Adv Med Oncol. 2022; 14:17588359221119318. PMC: 9434679. DOI: 10.1177/17588359221119318. View

16.

Calo P, Tuveri M, Pisano G, Tatti A, Medas F, Donati M . [Recurrent goitre: our experience]. Chir Ital. 2010; 61(5-6):545-9. View

17.

Catanzaro G, Sabato C, Russo M, Rosa A, Abballe L, Besharat Z . Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs). Int J Mol Sci. 2017; 18(12). PMC: 5751342. DOI: 10.3390/ijms18122742. View

18.

Illini O, Hochmair M, Fabikan H, Weinlinger C, Tufman A, Swalduz A . Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol. 2021; 13:17588359211019675. PMC: 8202258. DOI: 10.1177/17588359211019675. View

19.

Capp C, Wajner S, Siqueira D, Brasil B, Meurer L, Maia A . Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010; 20(8):863-71. DOI: 10.1089/thy.2009.0417. View

20.

Lyra J, Vinagre J, Batista R, Pinto V, Prazeres H, Rodrigues F . mTOR activation in medullary thyroid carcinoma with RAS mutation. Eur J Endocrinol. 2014; 171(5):633-40. DOI: 10.1530/EJE-14-0389. View